Effect of covariates on typical PK profiles of tacrolimus: A) formulation type, B) CYP3A5 genotype assuming the administration of Prograf® and C) total dose of tacrolimus (DTOT) assuming the administration of Prograf® (dose normalized blood concentration profiles) Prograf®, Limustin®, Framebin®, Tenacrine®, *1/*1, *1/*3, *3/*3, 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg